Skip to main content

Advertisement

Log in

Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 29 May 2015

Abstract

Background

Bis, also known as BAG3, has been identified as a Bcl-2-interacting protein that enhances cellular anti-apoptotic activity. It is involved in cellular differentiation, angiogenesis, migration, and invasion in various tumors. The purpose of this study was to investigate the Bis expression pattern, and the clinical significance thereof, in patients with resected lung cancer.

Methods

We studied 121 lung cancer patients who underwent curative surgical resection. Patient clinicopathological characteristics were reviewed retrospectively from medical records, including tumor recurrence and survival. The expression of Bis protein in lung cancer tissues was evaluated by immunohistochemical staining and was assessed using a four-tiered intensity score system (negative, weak, moderate, strong). Enhanced Bis expression at the periphery of a tumor facing the adjacent nontumor region was referred as “marginal activity.”

Results

Although Bis expression was higher in squamous cell carcinoma than in adenocarcinoma, marginal activity was higher in adenocarcinoma than in squamous cell carcinoma. All of the small cell carcinomas and lung cancer with neuroendocrine differentiation examined were negative for Bis expression. Compared with stage I lung cancer, patients with stage II and IIIA lung cancer exhibited higher Bis protein levels in lung tissues. Recurrence and survival rates did not differ significantly according to Bis expression intensity score or marginal activity.

Conclusions

Our study demonstrated that Bis expression differed according to the histological type and pathological stage of the lung cancer. Further studies are needed to assess its use as a biomarker and its role in the molecular pathogenesis of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Tanoue LT, Detterbeck FC. New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009;9:413–23.

    Article  PubMed  Google Scholar 

  3. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S–313S.

    Article  PubMed  CAS  Google Scholar 

  4. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409–17; discussioin 417-8.

    Article  PubMed  Google Scholar 

  5. Ohta Y, Tanaka Y, Watanabe G, Minato H. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J Exp Clin Cancer Res. 2007;26:301–5.

    PubMed  CAS  Google Scholar 

  6. Inoue M, Takakuwa T, Minami M, et al. Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008;135:830–6.

    Article  PubMed  Google Scholar 

  7. Ito T, Ishii G, Nagai K, et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer. 2009;63:418–24.

    Article  PubMed  Google Scholar 

  8. Lee JH, Takahashi T, Yasuhara N, et al. Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene. 1999;18:6183–90.

    Article  PubMed  CAS  Google Scholar 

  9. Doong H, Price J, Kim YS, et al. CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70. Oncogene. 2000;19:4385–95.

    Article  PubMed  CAS  Google Scholar 

  10. Doong H, Vrailas A, Kohn EC. What’s in the ‘BAG’? A functional domain analysis of the BAG-family proteins. Cancer Lett. 2002;188:25–32.

    Article  PubMed  CAS  Google Scholar 

  11. Rosati A, Ammirante M, Gentilella A, et al. Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol. 2007;39:1337–42.

    Article  PubMed  CAS  Google Scholar 

  12. Bonelli P, Petrella A, Rosati A, et al. BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia. 2004;18:358–60.

    Article  PubMed  CAS  Google Scholar 

  13. Liu P, Xu B, Li J, Lu H. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis. FEBS Lett. 2009;583:401–6.

    Article  PubMed  CAS  Google Scholar 

  14. Jung SE, Kim YK, Youn DY, et al. Down-modulation of Bis sensitizes cell death in C6 glioma cells induced by oxygen-glucose deprivation. Brain Res. 2010;1349:1–10.

    Article  PubMed  CAS  Google Scholar 

  15. Liao Q, Ozawa F, Friess H, et al. The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett. 2001;503:151-7.

    Article  PubMed  CAS  Google Scholar 

  16. Chiappetta G, Ammirante M, Basile A, et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab. 2007;92:1159–63.

    Article  PubMed  CAS  Google Scholar 

  17. Staibano S, Mascolo M, Di Benedetto M, et al. BAG3 protein delocalisation in prostate carcinoma. Tumour Biol. 2010;31:461–9.

    Article  PubMed  CAS  Google Scholar 

  18. Zhu H, Wu W, Fu Y, et al. Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. Ann Hematol. 2014;93:425–35.

    Article  PubMed  CAS  Google Scholar 

  19. Festa M, Del Valle L, Khalili K, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011;178:2504–12.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Rosati A, Bersani S, Tavano F, et al. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Am J Pathol. 2012;181:1524–9.

    Article  PubMed  CAS  Google Scholar 

  21. Zhang Y, Wang JH, Lu Q, Wang YJ. Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. Oncol Rep. 2012;27:109–13.

    PubMed  Google Scholar 

  22. Chiappetta G, Basile A, Barbieri A, et al. The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth. Oncotarget. 2014;5(16):6846–53.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.

    Article  PubMed  Google Scholar 

  24. Rosati A, Graziano V, De Laurenzi V, et al. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011;2:e141.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Wang HQ, Liu HM, Zhang HY, et al. Transcriptional upregulation of BAG3 upon proteasome inhibition. Biochem Biophys Res Commun. 2008;365:381–5.

    Article  PubMed  CAS  Google Scholar 

  26. Zhu H, Liu P, Li J. BAG3: a new therapeutic target of human cancers? Histol Histopathol. 2012;27:257–61.

    PubMed  CAS  Google Scholar 

  27. de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am. 2012;50:863–76.

    Article  PubMed  Google Scholar 

  28. Dong J, Guo L, Liao Z, et al. Increased expression of heat shock protein 70 in chronic obstructive pulmonary disease. Int Immunopharmacol. 2013;17:885–93.

    Article  PubMed  CAS  Google Scholar 

  29. Iwasaki M, Homma S, Hishiya A, et al. BAG3 regulates motility and adhesion of epithelial cancer cells. Cancer Res. 2007;67:10252–9.

    Article  PubMed  CAS  Google Scholar 

  30. Suzuki M, Iwasaki M, Sugio A, et al. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells. Cancer Lett. 2011;303:65–71.

    Article  PubMed  CAS  Google Scholar 

  31. Lee YD, Cui MN, Yoon HH, et al.: Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA, through NF-kappaB mediated activation of MMP-9. BMB Rep. 2014;47:262–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kassis JN, Guancial EA, Doong H, et al. CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Exp Cell Res. 2006;312:2962–71.

    Article  PubMed  CAS  Google Scholar 

  33. Fontanella B, Birolo L, Infusini G, et al. The co-chaperone BAG3 interacts with the cytosolic chaperonin CCT: new hints for actin folding. Int J Biochem Cell Biol. 2010;42:641–50.

    Article  PubMed  CAS  Google Scholar 

  34. Iwasaki M, Tanaka R, Hishiya A, et al. BAG3 directly associates with guanine nucleotide exchange factor of Rap1, PDZGEF2, and regulates cell adhesion. Biochem Biophys Res Commun. 2010;400:413–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National Research Foundation of Korea (NRF) Grants, funded by the Korean Government (MSIP) (Nos. 2014R1A2A1A11052422, 2012R1A1A2007589 and 2012R1A5A2047939).

Disclosures

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Seung Joon Kim MD, PhD or Jeong-Hwa Lee MD, PhD.

Additional information

Chang Dong Yeo and Gyeong Sin Park have contributed equally to this work.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yeo, C.D., Park, G.S., Kang, N. et al. Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance. Ann Surg Oncol 22 (Suppl 3), 1365–1370 (2015). https://doi.org/10.1245/s10434-015-4576-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4576-2

Keywords

Navigation